The START Center for Cancer Research
Chris Takimoto, MD, PhD, serves as the Global Chief Medical Officer at The START Center for Cancer Research starting October 2024, following a tenure as Chief Medical Officer at IGM Biosciences, Inc. from July 2021 to October 2024. Prior to this, Chris held various leadership roles in significant organizations, including Senior Vice President at Gilead Sciences and Chief Medical Officer at Forty Seven, Inc., specializing in Immuno-Oncology. Significant contributions to oncology stem from positions such as Vice President at Janssen Pharmaceutical Companies, Senior Director of Translational Medicine at Ortho Biotech, and Director of Pharmacology at The START Center for Cancer Care. Academic affiliations include an adjunct professor role at the University of Texas Health Science Center at San Antonio and chairing the Early Therapeutics Committee for the SWOG Cancer Research Network. Chris's educational background includes a dual MD and PhD from Yale, alongside fellowships in Medical Oncology and Clinical Pharmacology.
This person is not in any teams
The START Center for Cancer Research
2 followers
Deeply rooted in community oncology centers globally, the START Center for Cancer Research provides patients with access to specialized Phase 1 clinical trials for novel anti-cancer agents. With research sites in the United States and in Spain, Portugal, and Ireland, START’s clinical trial sites have conducted more than 1,300 early phase clinical trials, including for 43 therapies that have gained FDA/EMA approval. Founded in Texas in 2007, START today boasts 25 Principal Investigators (PIs) across its worldwide clinical trial sites. With over 100,000+ square feet of world-class research facilities, START offers patients comprehensive treatment plans that include multi-specialty services, genetic profiling of tumors, targeted therapies, state-of-the-art treatment technology, and advanced access to clinical research options. START is committed to accelerating passage from trials to treatments, and to delivering hope to patients, families, and physicians around the world.